The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
Lowe's
LOW · a US exchange · USD · Market cap $130.1B · 167,000 employees
Lowe's Companies, Inc., together with its subsidiaries, operates as a home improvement retailer in the United States and Canada.
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price219.14 USD at the 19 Nov 2026 close
- Our value readFair vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.68)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $171.90 to $255.52, base estimate $222.19 (screen dated 2026-11-19).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning political selling, disclosed 2026-10-22
- Options put/call open interest 0.68, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Lowe's holds its Markup at $219.14. Consolidating, no directional conviction, held for 19 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 19 days |
| Price at the screen | $219.14 |
| Valuation | 19.60 trailing · 17.91 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.81 |
Five Screens: LOW's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 82.52% | Below 33% | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 3.83% | Below 49% | Pass |
| Revenue purity | 0.14% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Lowe's's business is in a permissible area, but its interest-bearing debt is about 83% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LOW's ethical verdict changes
Today LOW does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 19 Nov 2026: it trades at roughly a 1% discount to our $222.19 fair value, 8.30% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 1.4% discount to the base estimate.
Third-party analyst targets: 33 covering, consensus Buy. The average target sits +16% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $222.19, with a range of $171.90 to $255.52, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Forward P/E | 17.9xexpensive even after accounting for its growth |
| Trailing P/E | 19.6xreasonably valued |
| EPS, trailing | 11.83 |
| EPS, forward | 12.95 |
| Revenue growth | +8.3%steady growth |
| Profit margin | 7.3%thin but positive margins |
| FCF yield | 3.55% |
| Dividend yield | 2.27% |
| Current ratio | 1.11adequate liquidity, worth monitoring |
| Beta | 0.81steadier than the market |
| Short interest, float | 0.02% |
| 52-week range | 178.45 - 293.06 |
| Market cap | $130.1B |
| Employees | 167,000 |
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (33 analysts) rates it buy, with a mean price target of $263.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Lowe's Companies, Inc. to Host 2026 Analyst and Investor Conference on Dec. 9 Yahoo Finance · 12h ago
- Ross Stores Earnings Due After Rival TJX Surged On Holiday Outlook Yahoo Finance · 12h ago
- Lowe's Strategic Investments Broaden Growth Algorithm, UBS Says Yahoo Finance · 13h ago
- Lowe's Companies (LOW) Could Be 12% Undervalued On Earnings Beat And Higher Guidance Yahoo Finance · 14h ago
- Tariff Refunds Are About A Fifth Of Target's Guidance Yahoo Finance · 15h ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | PRYOR JULIETTE WILLIAMS | Officer | 5,141 | · | |
| 2026-04-01 | BOLTZ WILLIAM P. | Officer | 9,535 | · | |
| 2026-04-01 | GODBOLE SEEMANTINI P | Chief Technology Officer | 9,145 | · | |
| 2026-04-01 | GRIGGS DAN CLAYTON JR. | Officer | 1,526 | · | |
| 2026-04-01 | SINK BRANDON J. | Chief Financial Officer | 8,349 | · | |
| 2026-04-01 | DUPRE JANICE M. | Officer | 5,185 | · | |
| 2026-04-01 | VANCE QUONTA D | Officer | 4,793 | · | |
| 2026-04-01 | VAGELL MARGRETHE R | Officer | 4,653 | · | |
| 2026-04-01 | MCFARLAND JOSEPH MICHAEL III | Officer | 9,535 | · | |
| 2026-04-01 | ELLISON MARVIN R | Chief Executive Officer | 37,292 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-22 | Pete Sessions | Republican | sell | 15K–50K |
| 2026-10-22 | Pete Sessions | Republican | sell | 15K–50K |
| 2026-10-22 | Pete Sessions | Republican | sell | 15K–50K |
| 2026-10-13 | Ro Khanna | Democrat | buy | 15K–50K |
| 2026-10-07 | Ro Khanna | Democrat | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $194.69 | +14.4% | $1.25 | $1,151 | +15.1% |
| 2 months | $191.28 | +16.5% | $1.25 | $1,171 | +17.1% |
| 3 months | $215.97 | +3.2% | $1.25 | $1,037 | +3.7% |
| 6 months | $212.36 | +4.9% | $2.50 | $1,061 | +6.1% |
| 1 year | $214.85 | +3.7% | $4.90 | $1,060 | +6.0% |
| 2 years | $260.70 | -14.6% | $9.60 | $891 | -10.9% |
| 3 years | $191.75 | +16.2% | $14.10 | $1,235 | +23.5% |
| 5 years | $225.88 | -1.4% | $22.10 | $1,084 | +8.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever LOW does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.